Monday, August 19, 2024 2:39:36 PM
"on to their next venture..." You're saying all the biopharma research and hired scientist researchers, and Lucid, and Cellynu are all a stock play to move onto the the next venture?
That's easy. Standard bitter generalization without specifics to back up your claims. The financials you copy/pasted counter your claims.
The company capex is valued more than the current marketcap.
The previous 201 reverse was former CEO Bokouri (sp?), who now court ordered has to payback $3M to the company.
They dividended Celly Nutrition. Did you get your Cellynu shares?
Cellynu controversy is when HUGE (now QNTM) started to tank, very heavily shorted by hate crew opponents, likely helped in part by the scammers on the Safeshot equation side.
That they hired stock milker Edward DeFeudis and his pump marketing company is to me not a positive sign, and suggests stock scam players. Maybe they wanted to counter the short attack, but that recent volume suggests lots of naked shorting.
What are you reading in the financials that shows this company is a scam play?
That's easy. Standard bitter generalization without specifics to back up your claims. The financials you copy/pasted counter your claims.
The company capex is valued more than the current marketcap.
The previous 201 reverse was former CEO Bokouri (sp?), who now court ordered has to payback $3M to the company.
They dividended Celly Nutrition. Did you get your Cellynu shares?
Cellynu controversy is when HUGE (now QNTM) started to tank, very heavily shorted by hate crew opponents, likely helped in part by the scammers on the Safeshot equation side.
That they hired stock milker Edward DeFeudis and his pump marketing company is to me not a positive sign, and suggests stock scam players. Maybe they wanted to counter the short attack, but that recent volume suggests lots of naked shorting.
What are you reading in the financials that shows this company is a scam play?
© 2024, by StockItOut
Recent QNTM News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/02/2026 12:30:03 PM
- Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied • GlobeNewswire Inc. • 04/02/2026 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/01/2026 12:02:04 PM
- Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis • GlobeNewswire Inc. • 04/01/2026 12:02:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/30/2026 11:50:09 AM
- Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis • GlobeNewswire Inc. • 03/30/2026 11:50:00 AM
- Quantum Biopharma Provides Corporate Update • GlobeNewswire Inc. • 03/27/2026 11:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/27/2026 12:10:03 PM
- Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status • GlobeNewswire Inc. • 03/27/2026 12:10:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/26/2026 12:00:10 PM
- Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis • GlobeNewswire Inc. • 03/26/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/23/2026 12:24:03 PM
- Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd • GlobeNewswire Inc. • 03/23/2026 12:24:00 PM
- Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering • GlobeNewswire Inc. • 03/20/2026 11:35:00 PM
- Quantum BioPharma Provides Corporate Update • GlobeNewswire Inc. • 03/11/2026 11:55:00 PM
- Quantum BioPharma Provides Corporate Update • GlobeNewswire Inc. • 03/10/2026 11:45:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/03/2026 02:19:46 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/23/2025 01:00:05 PM
- Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS) • GlobeNewswire Inc. • 12/23/2025 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/22/2025 09:23:02 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/22/2025 08:48:55 PM
- World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares • ACCESS Newswire • 12/22/2025 02:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/22/2025 12:00:04 PM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 12/11/2025 03:14:49 PM
- Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update • Newsfile • 12/11/2025 01:00:00 AM
